US equities
|
MU
$989.04
▼-3.88%
META
$742.96
▲+3.38%
NVDA
$226.32
▼-1.29%
SNDK
$1,487.33
▼-5.97%
SPCX
$163.42
▲+0.52%
MSFT
$541.15
▲+1.14%
AMD
$594.24
▼-2.28%
AAPL
$340.97
▲+1.29%
MU
$989.04
▼-3.88%
META
$742.96
▲+3.38%
NVDA
$226.32
▼-1.29%
SNDK
$1,487.33
▼-5.97%
SPCX
$163.42
▲+0.52%
MSFT
$541.15
▲+1.14%
AMD
$594.24
▼-2.28%
AAPL
$340.97
▲+1.29%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Repligen Corporation - Common Stock
(NQ:
RGEN
)
172.51
-1.37 (-0.79%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 12, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Repligen Corporation - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Why Freshworks Stock Bumped Higher Today
↗
October 06, 2026
It's about to join a famous small-cap stock index.
Via
The Motley Fool
Topics
Artificial Intelligence
Stocks
3 Healthcare Stocks That Concern Us
October 02, 2026
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have be...
Via
StockStory
3 Reasons to Avoid RGEN and 1 Stock to Buy Instead
September 09, 2026
Over the past six months, Repligen has been a great trade, beating the S&P 500 by 18.1%. Its stock price has climbed to $168.43, representing a healthy 31.7%...
Via
StockStory
Topics
Stocks
Repligen Corp (NASDAQ:RGEN) Combines Strong Growth with a Constructive Technical Setup
↗
September 05, 2026
Via
Chartmill
Repligen (NASDAQ:RGEN) Combines Strong Growth with a Promising Technical Breakout Setup
↗
July 30, 2026
Via
Chartmill
Repligen (NASDAQ:RGEN) Rallies as Quality Stock Delivers Earnings Beat
↗
July 28, 2026
Via
Chartmill
1 Profitable Stock on Our Buy List and 2 We Brush Off
August 28, 2026
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest ...
Via
StockStory
3 High-Flying Stocks with Warning Signs
August 24, 2026
“You get what you pay for” often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the ...
Via
StockStory
Topics
Supply Chain
3 Hyped Up Stocks We Keep Off Our Radar
August 21, 2026
The stocks featured in this article have all approached their 52-week highs. When these price levels hit, it typically signals strong business execution, pos...
Via
StockStory
Unpacking Q2 Earnings: Repligen (NASDAQ:RGEN) In The Context Of Other Drug Development Inputs & Services Stocks
August 16, 2026
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...
Via
StockStory
2 Growth Stocks to Add to Your Roster and 1 We Avoid
August 13, 2026
Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market va...
Via
StockStory
Topics
Credit Cards
Why Repligen (RGEN) Stock Is Up Today
July 28, 2026
What Happened? Shares of biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) jumped 14.6% in the afternoon session after the company reported ...
Via
StockStory
Topics
Artificial Intelligence
Repligen Q2 Earnings Call Highlights
↗
July 28, 2026
Repligen (NASDAQ:RGEN) reported second-quarter 2026 revenue of $204 million, up 12% year over year on a reported basis and 13% organically, as demand for proteins, analytics products and recurring...
Via
MarketBeat
Topics
Earnings
Which stocks are gapping on Tuesday?
↗
July 28, 2026
Via
Chartmill
Repligen (NASDAQ:RGEN) Posts Better-Than-Expected Sales In Q2 CY2026
July 28, 2026
Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 11.9% ...
Via
StockStory
Repligen (RGEN) Q2 Earnings: What To Expect
July 26, 2026
Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) will be reporting results this Tuesday morning. Here’s what you need to know. Repligen bea...
Via
StockStory
Hims & Hers Health, Repligen, West Pharmaceutical Services, and 10x Genomics Stocks Trade Down, What You Need To Know
July 24, 2026
What Happened? A number of stocks fell in the morning session after concerns grew over a rising number of uninsured patients. The trend was highlighted in HC...
Via
StockStory
3 Cash-Producing Stocks That Concern Us
July 24, 2026
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Luc...
Via
StockStory
Repligen to Buy BioLife Solutions for $1.5 Billion, Expanding Cell Therapy Reach
↗
July 22, 2026
Repligen (NASDAQ:RGEN) said it has signed a definitive agreement to acquire BioLife Solutions in a transaction valued at approximately $1.5 billion, adding a cell therapy-focused platform that...
Via
MarketBeat
Why Repligen (RGEN) Stock Is Trading Lower Today
July 21, 2026
What Happened? Shares of biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) fell 7% in the morning session after investors reacted to the com...
Via
StockStory
3 Reasons RGEN is Risky and 1 Stock to Buy Instead
July 08, 2026
Over the last six months, Repligen’s shares have sunk to $139.83, producing a disappointing 16% loss - a stark contrast to the S&P 500’s 9% gain. This might ...
Via
StockStory
Topics
Stocks
Supply Chain
2 High-Flying Stocks on Our Watchlist and 1 We Find Risky
June 25, 2026
Expensive stocks typically earn their valuations through superior growth rates that other companies simply can’t match. The flip side though is that these lo...
Via
StockStory
2 Profitable Stocks on Our Watchlist and 1 Facing Challenges
June 19, 2026
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifi...
Via
StockStory
3 Out-of-Favor Stocks We Keep Off Our Radar
May 22, 2026
Hitting a new 52-week low can be a pivotal moment for any stock. These floors often mark either the beginning of a turnaround story or confirmation that a co...
Via
StockStory
Q1 Rundown: Repligen (NASDAQ:RGEN) Vs Other Drug Development Inputs & Services Stocks
May 18, 2026
As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the drug development inputs & services ind...
Via
StockStory
Why Repligen (RGEN) Stock Is Trading Up Today
May 15, 2026
What Happened? Shares of biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) jumped 2.9% in the afternoon session after RBC Capital resumed co...
Via
StockStory
Topics
Artificial Intelligence
Economy
1 Growth Stock with Explosive Upside and 2 Facing Headwinds
May 15, 2026
Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived thr...
Via
StockStory
Repligen, AdaptHealth, and IQVIA Stocks Trade Down, What You Need To Know
May 13, 2026
What Happened? A number of stocks fell in the afternoon session after the April PPI report showed wholesale inflation accelerating to 6% annually, with servi...
Via
StockStory
Topics
Economy
5 Revealing Analyst Questions From Repligen’s Q1 Earnings Call
May 12, 2026
Repligen’s first quarter results were met positively by the market, reflecting solid execution across core product lines and robust demand in both analytics ...
Via
StockStory
Topics
Earnings
3 Small-Cap Stocks We Steer Clear Of
May 12, 2026
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and...
Via
StockStory
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
